Parenteral products represent a major growth engine in today’s surging global biopharma market. Their share of the global market figures to grow from 53% in 2020 ($606bn) to 57% in 2027 ($1,298bn)1, outpacing other routes of administration. On average, more than 40% of the medications approved by the FDA are injectable, with subcutaneous and intramuscular products making up a growing percentage of those approvals.2,3
As more and more injectables enter the global pipeline, these new assets are facing major shifts in market expectations and lifecycle success factors. In today’s market, it takes far more than a promising molecule and a validated therapeutic target for new products to gain traction. Differentiating user experience, patient-centric features, and other commercial success factors are now as critical as the drug substance and its mechanism of action—not to mention the injectable delivery system that will be used to administer that new treatment.
Four major trends are driving these shifts in the lifecycle roadmap for new injectables. Steps to address these forces are already a critical feature of a truly integrated, efficient, and resilient drug development and manufacturing processes.
Patient-centricity will be critical to the next generation of injectable products. For many users, the delivery experience is will be as important as the drug.
Peter Soelkner, Managing Director